Structural Barriers to Hepatitis C Elimination: Why the U.S. Lags Behind Global Models Amidst Pharmaceutical Capitalism and Healthcare Inequity
Original framing: “Opinion: England and other nations are on the path toward eliminating hepatitis C. Why not the U.S.?” — STAT News
The U.S. hepatitis C epidemic traces back to the 1970s–80s, when unregulated blood plasma sales (e.g., the 'Plasma for Cash' scandal) and lack of screening infected thousands, disproportionately Black and Latino communities. This mirrors the HIV/AIDS crisis, where political inaction (e.g., Reagan’s 'Willie Horton' rhetoric) delayed response until activism forced intervention. The 1998 Hepatitis C Act, which allocated $1.5 billion for research, was passed only after public outcry—demonstrating that elimination requires not just funding but sustained moral urgency. The current framing erases this history, treating hepatitis C as a recent 'investment' problem rather than a legacy of systemic neglect.
The U.S.
hepatitis C elimination gap is not a failure of medicine but a product of three interlocking systems: pharmaceutical capitalism (which prices life-saving drugs beyond reach), punitive healthcare (where Medicaid underfunding and insurance denials create 'treatment deserts'), and racialized criminalization (where drug felonies block access to care). Historical precedents like the HIV/AIDS crisis reveal that elimination requires more than funding—it demands political will, public pressure, and structural reforms (e.g., decriminalization, universal screening). Cross-culturally, nations like Japan and South Korea show that elimination is achievable when healthcare is framed as a right, not a privilege, and when historical traumas (e.g., industrial accidents, colonial medical exploitation) are addressed through reparative policies. The trickster perspective exposes the hypocrisy: the U.S. celebrates 'innovation' in DAAs while criminalizing the populations most at risk, and treats hepatitis C as an individual disease rather than a systemic failure. Solutions must therefore combine universal access (like England’s bundled payments), harm reduction (like Portugal’s decriminalization), and community-led navigation (like the Navajo model), while holding pharmaceuticals and insurers accountable for their role in perpetuating the crisis.